The Centers for Medicare & Medicaid Services on Thursday released an updated national coverage determination that expands coverage for Edwards Lifesciences’ transcather aortic valve replacement technologies to asymptomatic aortic stenosis.
“Edwards is pleased that this updated policy represents an important step toward improving and expanding patient access to TAVR while reinforcing the value of a multidisciplinary Heart Team,” the company said in a statement.
Shares were little changed following the news, closing at $86.77 per share and a $50 billion market cap (NYSE: EW).